Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24099523 | 0.94 | TSHR (0.50) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL16798998 | 0.92 | TSHR (0.51) | TSHRTHRBLMNAEPHX2ADRA1A | |
| SCHEMBL18039471 | 0.90 | THRB (0.43) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL16799301 | 0.89 | TSHR (0.47) | TSHRTHRBLMNAEPHX2ADRA1A | |
| SCHEMBL4918092 | 0.89 | TSHR (0.51) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL16425936 | 0.89 | TSHR (0.51) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL16799404 | 0.88 | TSHR (0.49) | TSHRTHRBEPHX2ADRA1APOLB | |
| SCHEMBL16799013 | 0.88 | TSHR (0.49) | TSHRTHRBEPHX2ADRA1APOLB | |
| SCHEMBL16799490 | 0.88 | TSHR (0.49) | TSHRTHRBEPHX2ADRA1APOLB | |
| SCHEMBL22939772 | 0.88 | TSHR (0.49) | TSHRTHRBLMNAEPHX2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0462670-B1 | Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to caboxylated particles & a kit containing same | JOHNSON & JOHNSON CLIN DIAG (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0462644-B1 | Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use | JOHNSON & JOHNSON CLIN DIAG (US) | 1995-10-18 | — | — | EP | claimed |
| US-5155166-A | Diagnostic kits for detecting antibodies or antigens; reacting active amine- or sulfhydryl-containing compound with quaternized carboxylic polymers | EASTMAN KODAK COMPANY (US) | 1992-10-13 | — | — | US | claimed |
| US-5147777-A | Analysis, diagnosis | EASTMAN KODAK COMPANY (US) | 1992-09-15 | — | — | US | claimed |
| EP-0462670-A1 | Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to caboxylated particles & a kit containing same | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-12-27 | — | — | EP | claimed |
| EP-0462644-A1 | Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-12-27 | — | — | EP | claimed |
| US-10352835-B2 | Ligand-functionalized substrates with enhanced binding capacity | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180217035-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2018-08-02 | — | — | US | disclosed |
| US-5888723-A | SENSITIVE HYBRIDIZATION ASSAY USING NUCLEIC ACID REAGENT COMPOSED OF OLIGONUCLEOTIDES COVALENTLY ATTACHED TO POLYMER PARTICLES WHICH ARE ADHERED TO SUPPORT USING WATER INSOLUBLE ADHESIVE; LOW BACKGROUND | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0462670-B1 | Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to caboxylated particles & a kit containing same | JOHNSON & JOHNSON CLIN DIAG (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0530357-B1 | ELEMENT AND METHOD FOR NUCLEIC ACID AMPLIFICATION AND DETECTION USING ADHERED PROBES | JOHNSON & JOHNSON CLIN DIAG (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0468585-B1 | Biologically active reagent, analytical element and methods for use of the reagent | JOHNSON & JOHNSON CLIN DIAG (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0462644-B1 | Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use | JOHNSON & JOHNSON CLIN DIAG (US) | 1995-10-18 | — | — | EP | disclosed |
| US-5262297-A | Medical diagnosis with active materials bound to polymers | EASTMAN KODAK COMPANY (US) | 1993-11-16 | — | — | US | disclosed |
| US-5200315-A | Nonporous particle is coated with copolymer of ethylene unsaturated reacted group, acrylic group with alkylene oxide branching and oleophilic addition monomers bonded to biological active substance; water insoluble; detection | EASTMAN KODAK COMPANY (US) | 1993-04-06 | — | — | US | disclosed |
| US-5155166-A | Diagnostic kits for detecting antibodies or antigens; reacting active amine- or sulfhydryl-containing compound with quaternized carboxylic polymers | EASTMAN KODAK COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5147777-A | Analysis, diagnosis | EASTMAN KODAK COMPANY (US) | 1992-09-15 | — | — | US | disclosed |
| EP-0468585-A2 | Biologically active reagent, analytical element and methods for use of the reagent | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1992-01-29 | — | — | EP | disclosed |
| EP-0462670-A1 | Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to caboxylated particles & a kit containing same | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0462644-A1 | Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180217035-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | ILK, EPCAM, ECPAS | TSHR 3878/4885THRB 2283/4885LMNA 1502/4885 |
| US-10352835-B2 | Ligand-functionalized substrates with enhanced binding capacity | ILK, EPCAM, ECPAS | TSHR 3878/4885THRB 2283/4885LMNA 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.